在HLA-B44超型分子中缺乏流感衍生的免疫性
Samuel Liwei Leong1,2, Janesha C Maddumage1,2, Stephanie Gras1,2,3
1Infection and Immunity Program, La Trobe Institute for Molecular Science (LIMS) La Trobe University Bundoora VIC Australia.
Clinical & translational immunology
|September 22, 2025
概括
设计一个CD8+T细胞疫苗面临着HLA多态性挑战. 虽然HLA超型组合类似的分子,但免疫原性有所不同,这意味着超型单独无法选择有效的疫苗标.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 结构生物学 结构生物学
背景情况:
- CD8+ T细胞对流感免疫至关重要,引发了对T细胞介导疫苗的兴趣.
- 人类白细胞抗原I类 (HLA-I) 多态性对疫苗设计构成重大障碍.
- 由结动机定义的HLA超型提供了解决HLA多样性的潜在策略.
研究的目的:
- 在HLA-B44超型中研究流感衍生的 (NS1195-203) 的呈现和免疫性.
- 预测由各种HLA-B44超型分子结合的的结构复合物.
- 评估具有不同HLA-B44超型分子的个体对的CD8+T细胞反应.
主要方法:
- 利用TFold和AlphaFold2进行-HLA复合物的结构预测.
- 包括HLA-B*44:02,HLA-B*44:03,HLA-B*40:01,以及HLA-B*45:01在HLA-B44超级型中.
- 从外围血液单核细胞 (PBMC) 生成的CD8+T细胞系,并通过细胞内细胞因子染色评估免疫原性.
主要成果:
- 预测的结构显示了相似之处,在P9-Trp残留物中发现了变化.
- 在HLA-B*44:03+和HLA-B*44:02+个体中观察到NS1195-203的多功能CD8+T细胞反应.
- 在具有其他HLA-B44超型分子的个体中检测到最小的T细胞反应.
结论:
- 虽然HLA超型对于预测呈现有用,但不能保证免疫性.
- 单独的HLA超型不足以选择疫苗表位.
- 对HLA超型的进一步研究可以有助于选集,以获得更广泛的疫苗适用性.
更多相关视频
相关概念视频
Leaky Scanning
5.6K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.6K
Antigens Involved in Adaptive Immunity
1.3K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.3K


